A Single-Center Observational Study on the Impact of Symptom Assessment Timing on the Short-Term Efficacy of 5-ASA Therapy in Patients With Initial-Onset or Relapsed Mild-to-Moderate Active Ulcerative Colitis

Specialist doctors decide the administration method of 5-ASA based on the patient's condition (all groups), mainly including topical therapy, or oral therapy (2-4 gram/day).

Participants in all groups will receive a standard Colon Endoscopy Procedure at 48-week.

Participants in will receive a standard Blood Routine Test at 4-week.

Participants in will receive a standard Blood Routine Test at 8-week.

Participants in will receive a standard Blood Routine Test at 12-week.

Participants in will receive a standard Stool Routine Test at 4-week.

Participants in will receive a standard Stool Routine Test at 8-week.

Participants in will receive a standard Stool Routine Test at 12-week.

Participants in will receive a standard Erythrocyte Sedimentation Rate Test at 4-week.

Participants in will receive a standard Erythrocyte Sedimentation Rate Test at 8-week.

Participants in will receive a standard Erythrocyte Sedimentation Rate Test at 12-week.

Participants in will receive a standard C-reactive Protein Test at 4-week.

Participants in will receive a standard C-reactive Protein Test at 8-week.

Participants in will receive a standard C-reactive Protein Test at 12-week.

Participants in will receive a standard Liver Function Test at 4-week.

Participants in will receive a standard Liver Function Test at 8-week.

Participants in will receive a standard Liver Function Test at 12-week.

Participants in will receive a standard Kidney Function Test at 4-week.

Participants in will receive a standard Kidney Function Test at 8-week.

Participants in will receive a standard Kidney Function Test at 12-week.